Filing Overview
Pharming Group N.V. filed a Form 6-K for March 2023 incorporating press releases dated March 12 and March 13, 2023. The disclosures address the Company’s deposits with Silicon Valley Bank in the United States and the United Kingdom. No quarterly or annual operating results are reported.
Financial Position and Liquidity
- Total cash and cash equivalents, together with restricted cash, were approximately US$209 million as of December 31, 2022.
- Pharming held approximately US$26 million at Silicon Valley Bank in the United States, largely uninsured at the time of disclosure.
- Pharming held approximately US$19 million at Silicon Valley Bank UK, with deposits largely exceeding the applicable protected limit.
- The filing provides no revenue, profit, cash-flow, margin, debt-balance, or other operating-performance metrics for the reporting period.
Material Changes and Unusual Items
- The Federal Deposit Insurance Corporation was appointed receiver of Silicon Valley Bank in the United States, while Silicon Valley Bank UK entered a government-facilitated sale process.
- On March 13, 2023, Silicon Valley Bank UK was sold to HSBC UK Bank plc. Pharming stated that customer deposits were protected and expected to have access to its approximately US$19 million deposit without loss.
- Recovery of the approximately US$26 million deposited with the U.S. bank remained uncertain as to both amount and timing at the date of the initial disclosure.
Outlook, Commentary, and Risks
Management stated that, based on Pharming’s strong balance sheet and operating cash flows, the bank failures were not expected to materially affect operating plans, convertible debt-service obligations, or other material cash requirements over the next twelve months and beyond.
The Company continued to monitor the situation and intended to pursue recovery of funds held at the U.S. and U.K. banks as necessary. The expected recovery of the U.K. deposit was subject to the implementation of the government-supported transaction. The U.S. deposit remained subject to recovery proceedings, with no clear recovery amount or timetable provided.
The releases contain customary forward-looking statement risks, including uncertainty regarding bank proceedings and cash recovery, clinical and commercial development, regulatory and technical matters, clinical-trial scope and costs, and working-capital requirements.
Key Facts to Verify
- Whether Pharming obtained full access to the approximately US$19 million previously held at Silicon Valley Bank UK and incurred no loss.
- The ultimate recovery amount and timing for the approximately US$26 million held at Silicon Valley Bank in the United States.
- The treatment of these deposits and any related loss, impairment, or disclosure in subsequent financial statements.
- Whether the Company’s operating cash flows and liquidity remained sufficient for convertible debt service and planned cash requirements.
- Any subsequent updates to Pharming’s cash balances, banking relationships, or liquidity outlook.